NCT03950609 2026-03-19
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
23 trialsNCT05824468 2026-03-10
Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer
Sun Yat-sen University
Phase 2 Active not recruiting
NCT05824481 2026-03-10
Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer
Sun Yat-sen University
Phase 2 Active not recruiting
NCT05012371 2026-03-05
Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04321954 2026-02-27
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
Massachusetts Eye and Ear Infirmary
Phase 2 Active not recruiting
NCT04781088 2026-02-11
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05273554 2026-01-12
A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04207086 2025-12-16
Neo PeLe
Melanoma Institute Australia
Phase 2 Active not recruiting
NCT05433116 2025-12-02
Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC
Universität des Saarlandes
Phase 2 Active not recruiting
NCT05282901 2025-11-24
PLUME
Institut Curie
Phase 2 Active not recruiting
NCT04869137 2025-10-31
Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT04209660 2025-10-07
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT02562118 2025-09-25
Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer
National University Hospital, Singapore
Phase 1/2 Active not recruiting
NCT04929392 2025-09-04
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT05114421 2025-08-07
Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05078931 2025-07-30
A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients
Shanghai Chest Hospital
Phase 2 Active not recruiting
NCT05308901 2025-07-25
Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma
Providence Health & Services
Phase 2 Active not recruiting
NCT02780310 2025-06-05
Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04393350 2025-02-26
Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
Emory University
Phase 2 Active not recruiting
NCT04745988 2024-11-15
An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients with Gastric Cancer
National Cancer Center Hospital East
Phase 2 Active not recruiting
NCT04287829 2024-11-05
PEMMELA
The Netherlands Cancer Institute
Phase 2 Active not recruiting
NCT05258279 2024-08-28
Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations
Juntendo University
Phase 2 Active not recruiting
NCT06138769 2024-07-03
Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma
Asan Medical Center
Phase 2 Active not recruiting